Patents by Inventor Ian Richard Anselm Peak
Ian Richard Anselm Peak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8962801Abstract: Neisseria meningitidis PorA constructs are provided which have one or more disrupted variable regions created by insertion of entire conserved regions or conserved region amino acids. The highly immunogenic variable regions of PorA are responsible for eliciting strain-specific immune responses that are not broadly protective, so disruption of the variable regions directs the immune response against conserved region epitopes to effectively immunize against a broader spectrum of N. meningitidis strains. Also provided are encoding nucleic acids, genetic constructs, host cells expressing the PorA constructs and compositions, kits and methods for detection and treatment of Neisseria meningitidis infections.Type: GrantFiled: August 1, 2011Date of Patent: February 24, 2015Assignee: Griffith UniversityInventors: Michael Paul Jennings, Ian Richard Anselm Peak
-
Publication number: 20130196901Abstract: Neisseria meningitidis PorA constructs are provided which have one or more disrupted variable regions created by insertion of entire conserved regions or conserved region amino acids. The highly immunogenic variable regions of PorA are responsible for eliciting strain-specific immune responses that are not broadly protective, so disruption of the variable regions directs the immune response against conserved region epitopes to effectively immunize against a broader spectrum of N. meningitidis strains. Also provided are encoding nucleic acids, genetic constructs, host cells expressing the PorA constructs and compositions, kits and methods for detection and treatment of Neisseria meningitidis infections.Type: ApplicationFiled: August 1, 2011Publication date: August 1, 2013Applicant: GRIFFITH UNIVERISTYInventors: Michael Paul Jennings, Ian Richard Anselm Peak
-
Publication number: 20130085262Abstract: The invention provides a novel surface polypeptide from Neisseria meningitidis as well as nucleic acid and nucleic acid sequence homologues encoding this protein. Pharmaceutical compositions containing the polypeptide and nucleic acids of the invention are also disclosed as well as methods useful in the treatment, prevention and diagnosis of N. meningitidis infection.Type: ApplicationFiled: September 14, 2011Publication date: April 4, 2013Applicant: The University of QueenslandInventors: Ian Richard Anselm PEAK, Michael Paul Jennings, E. Richard Moxon
-
Patent number: 8383790Abstract: Novel proteins that constitute modified forms of a Neisseria meningitidis surface antigen and encoding nucleic acids are provided. The modified surface proteins are characterized by having deletions of non-conserved amino acids, and thereby being capable of eliciting cross-protective immune responses against Neisseria meningitidis. The invention extends to the use of the modified surface antigens in diagnostics, in therapeutic and prophylactic vaccines and in the design and/or screening of medicaments. The modified surface antigens are particularly useful in vaccines which effectively immunize against a broader spectrum of N. meningitidis strains than would be expected from a corresponding wild-type surface antigen.Type: GrantFiled: October 31, 2007Date of Patent: February 26, 2013Assignee: The University of QueenslandInventors: Ian Richard Anselm Peak, Michael Paul Jennings
-
Patent number: 8367070Abstract: Novel proteins that constitute modified forms of a Neisseria meningitidis surface antigen and encoding nucleic acids are provided. The modified surface proteins are characterized by having deletions of non-conserved amino acids, and thereby being capable of eliciting cross-protective immune responses against Neisseria meningitidis. The invention extends to the use of the modified surface antigens in diagnostics, in therapeutic and prophylactic vaccines and in the design and/or screening of medicaments. The modified surface antigens are particularly useful in vaccines which effectively immunize against a broader spectrum of N. meningitidis strains than would be expected from a corresponding wild-type surface antigen.Type: GrantFiled: October 31, 2007Date of Patent: February 5, 2013Assignee: The University of QueenslandInventors: Ian Richard Anselm Peak, Michael Paul Jennings
-
Publication number: 20120123093Abstract: The invention provides a novel surface polypeptide from Neisseria meningitidis as well as nucleic acid and nucleic acid sequence homologues encoding this protein. Pharmaceutical compositions containing the polypeptide and nucleic acids of the invention are also disclosed as well as methods useful in the treatment, prevention and diagnosis of N. meningitidis infection.Type: ApplicationFiled: September 14, 2011Publication date: May 17, 2012Applicant: The University of QueenslandInventors: Ian Richard Anselm PEAK, Michael Paul Jennings, E. Richard Moxon
-
Patent number: 8034358Abstract: The invention provides a novel surface polypeptide from Neisseria meningitidis as well as nucleic acid and nucleic acid sequence homologues encoding this protein. Pharmaceutical compositions containing the polypeptide and nucleic acids of the invention are also disclosed as well as methods useful in the treatment, prevention and diagnosis of N. meningitidis infection.Type: GrantFiled: July 12, 2007Date of Patent: October 11, 2011Assignee: The University of QueeslandInventors: Ian Richard Anselm Peak, Michael Paul Jennings, E. Richard Moxon
-
Patent number: 7947291Abstract: Novel proteins that constitute modified forms of a Neisseria meningitidis surface antigen and encoding nucleic acids are provided. The modified surface proteins are characterized by having deletions of non-conserved amino acids, and thereby being capable of eliciting cross-protective immune responses against Neisseria meningitidis. The invention extends to the use of the modified surface antigens in diagnostics, in therapeutic and prophylactic vaccines and in the design and/or screening of medicaments. The modified surface antigens are particularly useful in vaccines which effectively immunize against a broader spectrum of N. meningitidis strains than would be expected from a corresponding wild-type surface antigen.Type: GrantFiled: January 25, 2001Date of Patent: May 24, 2011Assignee: The University of QueenslandInventors: Ian Richard Anselm Peak, Michael Paul Jennings
-
Publication number: 20100331537Abstract: The invention provides a novel surface polypeptide from Neisseria meningitidis as well as nucleic acid and nucleic acid sequence homologues encoding this protein. Pharmaceutical compositions containing the polypeptide and nucleic acids of the invention are also disclosed as well as methods useful in the treatment, prevention and diagnosis of N. meningitidis infection.Type: ApplicationFiled: July 22, 2010Publication date: December 30, 2010Applicant: THE UNIVERSITY OF QUEENSLANDInventors: IAN RICHARD ANSELM PEAK, MICHAEL PAUL JENNINGS, E. RICHARD MOXON
-
Publication number: 20090270591Abstract: The invention provides a novel surface polypeptide from Neisseria meningitidis as well as nucleic acid and nucleic acid sequence homologues encoding this protein. Pharmaceutical compositions containing the polypeptide and nucleic acids of the invention are also disclosed as well as methods useful in the treatment, prevention and diagnosis of N. meningitidis infection.Type: ApplicationFiled: July 12, 2007Publication date: October 29, 2009Inventors: Ian Richard Anselm PEAK, Michael Paul Jennings, E. Richard Moxon
-
Publication number: 20090068216Abstract: Novel proteins that constitute modified forms of a Neisseria meningitidis surface antigen and encoding nucleic acids are provided. The modified surface proteins are characterized by having deletions of non-conserved amino acids, and thereby being capable of eliciting cross-protective immune responses against Neisseria meningitidis. The invention extends to the use of the modified surface antigens in diagnostics, in therapeutic and prophylactic vaccines and in the design and/or screening of medicaments. The modified surface antigens are particularly useful in vaccines which effectively immunize against a broader spectrum of N. meningitidis strains than would be expected from a corresponding wild-type surface antigen.Type: ApplicationFiled: October 31, 2007Publication date: March 12, 2009Applicant: THE UNIVERSITY OF QUEENSLANDInventors: Ian Richard Anselm PEAK, Michael Paul JENNINGS
-
Publication number: 20090068229Abstract: Novel proteins that constitute modified forms of a Neisseria meningitidis surface antigen and encoding nucleic acids are provided. The modified surface proteins are characterized by having deletions of non-conserved amino acids, and thereby being capable of eliciting cross-protective immune responses against Neisseria meningitidis. The invention extends to the use of the modified surface antigens in diagnostics, in therapeutic and prophylactic vaccines and in the design and/or screening of medicaments. The modified surface antigens are particularly useful in vaccines which effectively immunize against a broader spectrum of N. meningitidis strains than would be expected from a corresponding wild-type surface antigen.Type: ApplicationFiled: October 31, 2007Publication date: March 12, 2009Applicant: THE UNIVERSITY OF QUEENSLANDInventors: Ian Richard Anselm Peak, Michael Paul Jennings
-
Publication number: 20050058660Abstract: The invention provides a novel surface polypeptide from Neisseria meningitidis as well as nucleic acid and nucleic acid sequence homologues encoding this protein. Pharmaceutical compositions containing the polypeptide and nucleic acids of the invention are also disclosed as well as methods useful in the treatment, prevention and diagnosis of N. meningitidis infection.Type: ApplicationFiled: August 11, 2003Publication date: March 17, 2005Inventors: Ian Richard Anselm Peak, Michael Paul Jennings, E. Richard Moxon
-
Patent number: 6607729Abstract: The invention provides a novel surface polypeptide from Neisseria meningitidis as well as nucleic acid and nucleic acid sequence homologues encoding this protein. Pharmaceutical compositions containing the polypeptide and nucleic acids of the invention are also disclosed as well as methods useful in the treatment, prevention and diagnosis of N. meningitidis infection.Type: GrantFiled: March 5, 2001Date of Patent: August 19, 2003Assignee: The University of QueenslandInventors: Ian Richard Anselm Peak, Michael Paul Jennings, E. Richard Moxon
-
Patent number: 6495345Abstract: The invention provides a novel surface polypeptide from Neisseria meningitidis as well as nucleic acid and nucleic acid sequence homologues encoding this protein. Pharmaceutical compositions containing the polypeptide and nucleic acids of the invention are also disclosed as well as methods useful in the treatment, prevention and diagnosis of N. meningitidis infection.Type: GrantFiled: September 26, 2000Date of Patent: December 17, 2002Assignee: The University of QueenslandInventors: Ian Richard Anselm Peak, Michael Paul Jennings, E. Richard Moxon
-
Publication number: 20020160016Abstract: Novel proteins that constitute modified forms of a Neisseria meningitidis surface antigen and encoding nucleic acids are provided. The modified surface proteins are characterized by having deletions of non-conserved amino acids, and thereby being capable of eliciting cross-protective immune responses against Neisseria meningitidis. The invention extends to the use of the modified surface antigens in diagnostics, in therapeutic and prophylactic vaccines and in the design and/or screening of medicaments. The modified surface antigens are particularly useful in vaccines which effectively immunize against a broader spectrum of N. meningitidis strains than would be expected from a corresponding wild-type surface antigen.Type: ApplicationFiled: January 25, 2001Publication date: October 31, 2002Inventors: Ian Richard Anselm Peak, Michael Paul Jennings
-
Publication number: 20020102276Abstract: The invention provides a novel surface polypeptide from Neisseria meningitidis as well as nucleic acid and nucleic acid sequence homologues encoding this protein. Pharmaceutical compositions containing the polypeptide and nucleic acids of the invention are also disclosed as well as methods useful in the treatment, prevention and diagnosis of N. meningitidis infection.Type: ApplicationFiled: March 5, 2001Publication date: August 1, 2002Inventors: Ian Richard Anselm Peak, Michael Paul Jennings, E. Richard Moxon
-
Patent number: 6197312Abstract: The invention provides a novel surface polypeptide from Neisseria meningitidis as well as nucleic acid and nucleic acid sequence homologues encoding this protein. Pharmaceutical compositions containing the polypeptide and nucleic acids of the invention are also disclosed as well as methods useful in the treatment, prevention and diagnosis of N. meningitidis infection.Type: GrantFiled: August 19, 1999Date of Patent: March 6, 2001Assignee: The University of QueenslandInventors: Ian Richard Anselm Peak, Michael Paul Jennings, E. Richard Moxon